48 / 74 · 0:55 · Original AXON film
Survodutide
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
Two receptor targets
Survodutide targets GLP-1 and glucagon receptors. In liver research, the important question extends beyond how much weight or liver fat changes. [1]
MASH | human phase 2 trial
A 2024 randomized phase two trial studied adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis, called MASH, and liver fibrosis over 48 weeks. [1]
A specific biopsy endpoint
The primary endpoint was improvement in MASH without worsening of fibrosis. More participants reached that endpoint with survodutide than with placebo. Gastrointestinal adverse events were frequent. [1]
Inflammation and fibrosis differ
Improved inflammation and improved scarring are different outcomes. A biopsy result at one time point also cannot establish prevention of liver failure or longer survival without further evidence. [1]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Sanyal et al. (2024): A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis →Dual receptor activity, 48-week design, biopsy-confirmed population, primary endpoint, and gastrointestinal adverse events.
